GREAT-2 was a phase II, placebo-controlled trial evaluating gremubamab, a bispecific monoclonal antibody, for chronic Pseudomonas aeruginosa infection in bronchiectasis. As part of our ATS 2025 coverage, Dr Merete Long discusses how this targeted therapy disrupts the vicious cycle of infection and inflammation, trial outcomes including significant bacterial load reduction and improved quality of life, and the broader implications for future treatment strategies.

In this Q&A, Professors David Price and David Halpin discuss their ATS 2025 abstract on improving COPD outcomes through a digital adherence support package. They explore the MAGNIFY trial's design, including how an EMR-driven algorithm identified high-risk patients and how a pharmacist-led intervention combined with a digital inhaler device significantly reduced treatment failure in a real-world primary care setting.

As part of our EAACI 2025 coverage, we spoke with Dr Eugenio De Corso (Catholic University of the Sacred Heart, Milan) around the EVEREST trial, a phase 4 head-to-head study comparing dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. Dr De Corso explores the study’s methodology, key findings, and implications for clinical practice in managing this challenging patient population.

The 2025 AAAAI and WAO joint congress highlighted advances in chronic rhinosinusitis (CRS) treatment. Notable studies presented positive results for novel biologic therapies, including tezepelumab, depemokimab and mepolizumab for chronic rhinosinusitis with nasal polyps (CRSwNP), and dupilumab for chronic rhinosinusitis without nasal polyps (CRSsNP). These findings highlight significant advancements in symptom management, offering hope for improved patient outcomes and reduced treatment burdens.

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted ...

Although there is limited evidence on the link between interstitial lung disease (ILD) and malnutrition, malnourished patients tend to have shorter survival rates, regardless of disease severity. A late-breaking abstract presented at ERS 2024 titled “Dietetic intervention in malnourished patients with interstitial lung disease (ILD): a pilot trial” investigated whether dietitian involvement could provide meaningful benefits to these patients, potentially laying the groundwork for further research and future clinical guidelines.

The BETTER-B study, recently presented at ERS and published in The Lancet Respiratory Medicine, provided new insights into the management of severe breathlessness in patients with chronic respiratory diseases such as COPD and Interstitial Lung Disease (ILD).  Severe breathlessness is a debilitating symptom that significantly impacts the quality of life for millions of people worldwide, yet there are currently no licensed medications to effectively address it outside of Australia. Given the clinical challenges and limited treatment options, clinicians often resort to off-label use of medications like mirtazapine, a widely prescribed antidepressant that appeared promising. Despite its initial promise, the study found that doses ranging from 15 to 45 mg of mirtazapine failed to provide significant relief compared to a placebo. Additionally, the findings highlighted potential adverse effects and increased healthcare costs associated with its use. 

The nasal airway serves as the primary entry point of air and oxygen into the body. It serves critical functions, such as providing a physical barrier against external irritants and pathogens and warming and humidifying incoming air.1 Consequently, disorders of ...

Pentraxin-2 is a member of the pentraxin family of proteins, which includes C-reactive protein (CRP), pentraxin-2 and pentraxin-3.1–3 When initially discovered and characterized, pentraxin-2 was known as serum amyloid P (SAP) due to its isolation from amyloid deposits in humans; ...